$NRIX

Nurix said Sanofi began a Phase 1 first-in-human trial of SAR448272/NX-3911, an oral STAT6 degrader, triggering a $10 million milestone payment. Nurix reported it has received about $139 million from its 2019 Sanofi collaboration and remains eligible for about $453 million in further STAT6-related milestones. Sanofi runs the trial, with U.S. co-development and co-promotion options for Nurix.

Morgan Stanley raised its Nurix Therapeutics (NRIX) price target to $38 from $36 and kept an Overweight rating. NRIX trades around $23.43, implying about 43% upside to the consensus target. The article also notes multiple other analyst target increases tied to Nurix’s Roche collaboration and clinical updates.

Nurix Therapeutics (Nasdaq: NRIX) reported fiscal Q2 2026 results and a corporate update. It entered a global Roche collaboration for bexobrutideg (NX-5948) with up to $2.3B total payments, including a $700M upfront. Nurix said EHA data showed CLL/SLL ORR of 83% (PFS 22.1 months) and cash of $443.5M as of May 31, 2026.

Nurix Therapeutics, Inc. (NRIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 nrix-20260709xexx991.htm EX-99.1 Document Exhibit 99.1 [Nurix logo] Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Entered into global collaboration with Roche for bexobrutideg, with potential total payments of up to $2.3

Nurix Therapeutics (NRIX) extended gains for an eighth straight session, reaching a 52-week high of $23.09 and closing up 16.37% at $22.46, according to trading data cited in the article. The move followed Nurix’s partnership with Roche to co-develop and commercialize bexobrutideg, with $700 million upfront and up to $2.3 billion in milestones, the companies said.

Ring Christine (Chief Legal Officer) sold 28,935 shares of Nurix Therapeutics, Inc. (NRIX) at $20.06 ($0.58M total) on 2026-06-25 under a Rule 10b5-1 trading plan.

DelveInsight reports the chronic spontaneous urticaria (CSU) market in the 7MM was about $2 billion in 2025, with roughly 4.8 million diagnosed prevalent cases, expected to rise by 2036. The US led in 2025. The report cites emerging therapies including Celldex’s barzolvolimab, Sanofi’s rilzabrutinib, and Jasper’s briquilimab, plus FDA approval of dupilumab for pediatric CSU.

Markets settled higher as inflation expectations eased; the 10-year breakeven rate fell to 2.452%. European yields rose, with Germany’s 10-year Bund at 3.060% (+2.2 bp) and UK gilt at 4.943% (+4.0 bp). Eurozone Sentix confidence improved to -3.4. Chipmakers rallied: Intel +11% after Google ordered 3 million Tensor Processing Units for 2028; others also gained.

US Treasury yields rose and European yields climbed, with German 10-year Bund at 3.045% and UK gilt at 4.913%. Eurozone Sentix confidence improved to -3.4. ECB swaps price a 100% chance of a 25 bp hike. US stocks rebounded: Micron and Intel up ~9%, chip/AI peers higher. Notable movers: Roche deal lifts Nurix up 17%; Cerebras gets $270 target; Wix falls on ~$50m 2026 bookings hit.

Nurix Therapeutics, Inc. (NRIX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. nrix-20260606 0001549595 false 06/06/2026 1600 Sierra Point Parkway Brisbane California 0001549595 2026-06-06 2026-06-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________ FORM 8-K __________________________________